Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
If you're experiencing chronic reflux, you may be at risk. Approximately 26% of gastroesophageal reflux disease (GERD) patients will progress to Barrett's.1 Other risk factors include tobacco use, obesity, hiatal hernia, and family history.2-7
Barrett’s is the primary risk factor for esophageal adenocarcinoma.9-11 Untreated Barrett's esophagus can increase your risk of developing this form of cancer by 50 times or more.9,11-14
If detected early, it's possible to treat Barrett’s esophagus and reduce your risk for esophageal adenocarcinoma.5,14,15
Information and resources on this site should not be used as a substitute for medical advice from your doctor. Always discuss diagnosis and treatment information including risks with your doctor. Keep in mind that all treatment and outcome results are specific to the individual patient. Results may vary.
Vaezi M, Zehrai A, Yuksel E. Testing for refractory gastroesophageal reflux disease: ASGE Leading Edge- American Society Gastroenterology Esdoscopy. 2012;2(2):1-13
Dymedex Market Development Consulting, Strategic Market Assessment, GERD, October 30, 2014. References 1-3, 6-15, 22, 23, 25, and 34 from the full citation list, access at http://www.medtronic.com/giclaims
Spechler S. et al. Barrett’s Esophagus. N Engl J Med. 2014; 371:836-45.
Evans JA et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointestinal Endoscopy. 2012;27(6):1087-1094
Shaheen NJ, Sharma P, et al. Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. New England Journal of Medicine. 2009 May;360(22):2277-2288.
Chak A, Lee T, Kinnard MF, et al. Familial aggregation of Barrett’s oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut. 2002 Sep;51(3):323-8
Anaparthy R, Gaddam S, Kanakadandi V, et al. Association Between Length of Barrett’s Esophagus and Risk of High-Grade Dysplasia or Adenocarcinoma in Patients Without Dysplasia. Clin Gastroenterol Hepatol. 2013 Nov;11(11):1430-6,
Coleman H, Bhat S et al. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidem. 2011 Sept;26(9):739-45
De Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030-6.
Pohl H, Welch G et al. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-6.
Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375-83.
Gilbert EW et al. Barrett’s esophagus: a review of the literature. J Gastrointest Surg. 2011;15:708-1.
Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9(3):220-7.
Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245-55.
Phoa KN, van Vilsteren FG, Pouw RE, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014 Mar 26;311(12):1209-17.